Patient with antithrombotic medication. Which do on bleedings or praeoperative?;Patient mit antithrombotischer medikation. Was tun bei blutungen oder präoperativ?

Laryngo- Rhino- Otologie

Volumn 85, Issue 1, 2006, Pages 50-62

  Stiefelhagen, P ^a  

^a Internistischen Abteilung   (Germany)

Author keywords

Antithrombotic medication; Atherothrombotic diseases; Heparins; INR; Thrombocyte aggregation inhibitor; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ANTIXA; CLOPIDOGREL; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; INNOHEP 20000; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; PENTASACCHARIDE; PHENPROCOUMON; TICLOPIDINE; UNCLASSIFIED DRUG; XIMELAGATRAN;

BRAIN INFARCTION; BRAIN ISCHEMIA; CHRONIC DISEASE; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FORAMEN OVALE; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG THROMBOSIS; LUNG EMBOLISM; PELVIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BLOOD COAGULATION TESTS; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PHENPROCOUMON; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; PREOPERATIVE CARE; PREVALENCE; PRIMARY PREVENTION; PULMONARY EMBOLISM; RISK FACTORS; SEX FACTORS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 32244434142     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870375     Document Type: Review

References (11)

1. Harenberg J. Thrombosetherapie mit niedermolekularem Heparin. Med Klin 2003; 98: 493-498
2. von Aken H, Bode C, Darius H, Dhiem C, Encke A, Gulba DC, Haas S, Hacke W, Puhl W, Quante M, Riess H, Scharf R, Schellong S, Schrör K, Schulte KL, Tebbe U. Anticoagulation: The present and the future. Clin Appl Thromb Hemost 2001; 7: 195-204
3. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662
4. Hirsh J, Sirausa S, Cosmi Bet al. Lown molecularweight heparins (LM-WH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-363
5. Büller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2004; 126: 401S-428S
6. Lagerstedt CI, Olsson CG, Fagher BO et al. Need for long-term anticoagulant treatment in Symptomatic calf-vein thrombosis. N Engl J Med 1979; 301: 855-858
7. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907
8. Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169
9. The Stroke Prevention in Atrial Fibrillation investigators. Watfarin versus aspirin for prevention of Throboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691
10. Hart RG et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501
11. Yusuf S, Zhao F, Metha SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502